{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:37:33Z","timestamp":1793320653741,"version":"4.5.0"},"reference-count":236,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.ctrv.2025.103046","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:56:46Z","timestamp":1762833406000},"page":"103046","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation"],"prefix":"10.1016","volume":"141","author":[{"given":"Reza","family":"Elahi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6565-4679","authenticated-orcid":false,"given":"Yassine","family":"Alami Idrissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8024-9401","authenticated-orcid":false,"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.ctrv.2025.103046_b0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241512224","article-title":"Hepatocellular Carcinoma: Latest Research in Pathogenesis, Detection and Treatment","volume":"24","author":"Foglia","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0010","doi-asserted-by":"crossref","first-page":"355","DOI":"10.3350\/cmh.2023.0070","article-title":"The latest global burden of liver cancer: a past and present threat","volume":"29","author":"Oh","year":"2023","journal-title":"Clin Mol Hepatol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0015","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ctrv.2025.103046_b0020","doi-asserted-by":"crossref","DOI":"10.1177\/10732748241293680","article-title":"Exploring the Impact of the \u03b2-Catenin Mutations in Hepatocellular Carcinoma: an In-Depth Review","volume":"31","author":"Idrissi","year":"2024","journal-title":"Cancer Control"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0025","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1053\/j.gastro.2015.12.041","article-title":"Evidence-based Diagnosis, Staging, and Treatment of patients with Hepatocellular Carcinoma","volume":"150","author":"Bruix","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2025.103046_b0030","doi-asserted-by":"crossref","DOI":"10.1007\/s40477-024-00965-x","article-title":"The correlation between metabolic dysfunction-associated steatotic liver disease (MASLD) grades and hemodynamic alterations of the portal, hepatic, and splenic vein and spleen size","author":"Borji","year":"2024","journal-title":"J Ultrasound"},{"key":"10.1016\/j.ctrv.2025.103046_b0035","article-title":"ALBI Grade Enables Risk Stratification for Bleeding events and Refines Prognostic Prediction in Advanced HCC following Atezolizumab and Bevacizumab","volume":"12(null):671\u201383","author":"Stefanini","year":"2025","journal-title":"Journal of Hepatocellular Carcinoma"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103046_b0040","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1056\/NEJMra1713263","article-title":"Hepatocellular Carcinoma","volume":"380","author":"Villanueva","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0045","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43066-023-00306-3","article-title":"Latest advances in hepatocellular carcinoma management and prevention through advanced technologies","volume":"14","author":"Addissouky","year":"2024","journal-title":"Egyptian Liver Journal"},{"issue":"10360","key":"10.1016\/j.ctrv.2025.103046_b0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103046_b0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217362","article-title":"Emerging targets in gastric and pancreatic cancer: Focus on claudin 18.2","volume":"611","author":"Tojjari","year":"2025","journal-title":"Cancer Lett"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103046_b0060","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0065","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3748\/wjg.v29.i6.1054","article-title":"Immunotherapy for hepatocellular carcinoma: current status and future perspectives","volume":"29","author":"Mandlik","year":"2023","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.ctrv.2025.103046_b0070","article-title":"Evaluating immune cell abundance across hepatocellular carcinoma disease stages I-III: Findings from TCGA analysis","volume":"43(4_suppl):621-","author":"Jaradat","year":"2025","journal-title":"J Clin Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103046_b0075","doi-asserted-by":"crossref","first-page":"1924","DOI":"10.1001\/jama.2024.19462","article-title":"CAR T Cells and T-Cell Therapies for Cancer: a Translational Science Review","volume":"332","author":"Brudno","year":"2024","journal-title":"J Am Med Assoc"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0080","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25052631","article-title":"Chimeric Antigen Receptor T Cell Therapy for Hepatocellular Carcinoma: where do we stand?","volume":"25","author":"Aggeletopoulou","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103046_b0085","article-title":"Immune Cell Hacking: challenges and Clinical Approaches to create Smarter Generations of Chimeric Antigen Receptor T Cells","volume":"9\u20132018","author":"Elahi","year":"2018","journal-title":"Front Immunol"},{"issue":"10254","key":"10.1016\/j.ctrv.2025.103046_b0090","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ctrv.2025.103046_b0095","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-2967","article-title":"FDA Approval Summary: Lisocabtagene Maraleucel for Second-Line Treatment of Large B-Cell Lymphoma","author":"Elmacken","year":"2024","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103046_b0100","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1093\/oncolo\/oyac163","article-title":"FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of adults with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"issue":"27","key":"10.1016\/j.ctrv.2025.103046_b0105","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103046_b0110","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oncolo\/oyac054","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncologist"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0115","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"FDA Approval Summary: Tisagenlecleucel for Treatment of patients with Relapsed or Refractory B-cell Precursor Acute Lymphoblastic Leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103046_b0120","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1158\/1078-0432.CCR-21-3803","article-title":"FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma","volume":"28","author":"Sharma","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0125","first-page":"1176","volume":"12","author":"Cilta-cel OK'd for Multiple Myeloma","year":"2022","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctrv.2025.103046_b0130","article-title":"Application and prospect analysis of chimeric antigen receptor T-cell therapy in hepatocellular carcinoma treatment: a systematic review and meta-analysis","volume":"16\u20132025","author":"Wu","year":"2025","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.103046_b0135","unstructured":"Esmaeilzadeh A, Jafari D, Elahi R, Bazargan M, Rafie MZ, Mansourabadi AH. Chimeric Antigen Receptor (CAR) T Cell Immunotherapy for Solid Tumors. Cham: Springer International Publishing. p. 1-48."},{"key":"10.1016\/j.ctrv.2025.103046_b0140","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.918869","article-title":"The tumor microenvironment of hepatocellular carcinoma and its targeting strategy by CAR-T cell immunotherapy","volume":"13","author":"Guizhen","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.ctrv.2025.103046_b0145","article-title":"A phase 1\/2 study of AZD5851, a chimeric antigen receptor (CAR) T-cell therapy directed against GPC3 in adult patients with advanced\/recurrent hepatocellular carcinoma (HCC)","volume":"42(16_suppl):TPS2675-TPS","author":"Hamilton","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0150","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s12015-023-10668-1","article-title":"Chimeric Antigen Receptor (CAR)-based Cell Therapy for Type 1 Diabetes Mellitus (T1DM); Current Progress and Future Approaches","volume":"20","author":"Mohammadi","year":"2024","journal-title":"Stem Cell Rev Rep"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0155","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2114254","article-title":"Current updates on generations, approvals, and clinical trials of CAR T-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","journal-title":"Hum Vaccin Immunother"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0160","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103046_b0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2023.122381","article-title":"Current progress of chimeric antigen receptor (CAR) T versus CAR NK cell for immunotherapy of solid tumors","volume":"337","author":"Esmaeilzadeh","year":"2024","journal-title":"Life Sci"},{"key":"10.1016\/j.ctrv.2025.103046_b0170","doi-asserted-by":"crossref","unstructured":"Ebrahimi F, Jabbari M, Mohammadi V, Karami P, Esmaeilzadeh K, Elahi R, et al. Nanobody-based chimeric antigen receptor (NbCAR) T cells for in-vivo cancer immunotherapy: A systematic review. 2024.","DOI":"10.21203\/rs.3.rs-4651034\/v1"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0175","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12061704","article-title":"CRISPR-Mediated Non-Viral Site-specific Gene Integration and Expression in T Cells: Protocol and Application for T-Cell Therapy","volume":"12","author":"Od\u00e9","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103046_b0180","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005189","article-title":"Automated, scaled, transposon-based production of CAR T cells","volume":"10","author":"Lock","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0185","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s12015-021-10246-3","article-title":"Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; recent advances and Future prospects","volume":"17","author":"Elahi","year":"2021","journal-title":"Stem Cell Rev Rep"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.beha.2024.101566","article-title":"Allogeneic \u201cOff-the-Shelf\u201d CAR T cells: challenges and advances","volume":"37","author":"Chen","year":"2024","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0195","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1002\/med.21455","article-title":"Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment","volume":"38","author":"Zhou","year":"2018","journal-title":"Med Res Rev"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0200","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0016-5085(03)00689-9","article-title":"Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma","volume":"125","author":"Capurro","year":"2003","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0205","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s13402-017-0364-2","article-title":"Role of Glypican-3 in the growth, migration and invasion of primary hepatocytes isolated from patients with hepatocellular carcinoma","volume":"41","author":"Montalbano","year":"2018","journal-title":"Cell Oncol (Dordr)"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103046_b0210","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1002\/ijc.29518","article-title":"High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy","volume":"137","author":"Haruyama","year":"2015","journal-title":"Int J Cancer"},{"issue":"24","key":"10.1016\/j.ctrv.2025.103046_b0215","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1158\/1078-0432.CCR-14-1170","article-title":"Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma","volume":"20","author":"Gao","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1089\/hum.2016.025","article-title":"Redirecting T Cells to Glypican-3 with 4-1BB Zeta Chimeric Antigen Receptors results in Th1 Polarization and Potent Antitumor activity","volume":"28","author":"Li","year":"2017","journal-title":"Hum Gene Ther"},{"key":"10.1016\/j.ctrv.2025.103046_b0225","first-page":"690","article-title":"Anti-GPC3-CAR T Cells Suppress the growth of Tumor Cells in Patient-Derived Xenografts of Hepatocellular Carcinoma","volume":"7","author":"Jiang","year":"2016","journal-title":"Front Immunol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0230","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.ymthe.2019.04.020","article-title":"Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma","volume":"27","author":"Wu","year":"2019","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2025.103046_b0235","doi-asserted-by":"crossref","unstructured":"Zhou L, Li Y, Zheng D, Zheng Y, Cui Y, Qin L, et al. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. Mol Ther Oncol. 2024;32(2):200817.","DOI":"10.1016\/j.omton.2024.200817"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0240","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004205","article-title":"Integrated use of PD-1 inhibition and transarterial chemoembolization for hepatocellular carcinoma: evaluation of safety and efficacy in a retrospective, propensity score-matched study","volume":"10","author":"Marinelli","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103046_b0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.21037\/tgh-24-44","article-title":"Neoadjuvant PD-1\/PD-L1 inhibitors plus chemotherapy in resectable gastric and gastroesophageal junction cancer","volume":"9","author":"Taherifard","year":"2024","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"7655","key":"10.1016\/j.ctrv.2025.103046_b0250","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature22396","article-title":"PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity","volume":"545","author":"Gordon","year":"2017","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0255","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/s12094-020-02397-5","article-title":"Anti-PD-1\/L1-associated immune-related adverse events as harbinger of favorable clinical outcome: systematic review and meta-analysis","volume":"23","author":"Park","year":"2021","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2025.103046_b0260","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/1782728","article-title":"Combination of AAV-CCL19 and GPC3 CAR-T Cells in the Treatment of Hepatocellular Carcinoma","volume":"2021","author":"Meng","year":"2021","journal-title":"J Immunol Res"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0265","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2023.5501","article-title":"Bispecific GPC3\/PD\u20111 CAR\u2011T cells for the treatment of HCC","volume":"62","author":"Li","year":"2023","journal-title":"Int J Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0270","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1158\/2326-6066.CIR-19-0293","article-title":"Glypican-3-specific CAR T Cells Coexpressing IL15 and IL21 have Superior expansion and Antitumor activity against Hepatocellular Carcinoma","volume":"8","author":"Batra","year":"2020","journal-title":"Cancer Immunol Res"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0275","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/j.ymthe.2023.01.002","article-title":"Targeting Lin28 axis enhances glypican-3-CAR T cell efficacy against hepatic tumor initiating cell population","volume":"31","author":"Patra","year":"2023","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0280","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24032539","article-title":"The Role of Alpha-Fetoprotein (AFP) in Contemporary Oncology: the Path from a Diagnostic Biomarker to an Anticancer Drug","volume":"24","author":"G\u0142owska-Ciemny","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0285","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.2174\/0929867327999200729151247","article-title":"Role of Alpha-Fetoprotein in Hepatocellular Carcinoma Drug Resistance","volume":"28","author":"Li","year":"2021","journal-title":"Curr Med Chem"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0290","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/1078-0432.CCR-16-1203","article-title":"Targeting Alpha-Fetoprotein (AFP)-MHC complex with CAR T-Cell Therapy for Liver Cancer","volume":"23","author":"Liu","year":"2017","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103046_b0295","article-title":"NKG2D: a Master Regulator of Immune Cell Responsiveness","volume":"9\u20132018","author":"Wensveen","year":"2018","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103046_b0300","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1158\/2326-6066.CIR-19-0026","article-title":"Eradication of Hepatocellular Carcinoma by NKG2D-based CAR-T Cells","volume":"7","author":"Sun","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0305","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s13046-014-0076-7","article-title":"MICA\/B expression is inhibited by unfolded protein response and associated with poor prognosis in human hepatocellular carcinoma","volume":"33","author":"Fang","year":"2014","journal-title":"J Exp Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103046_b0310","doi-asserted-by":"crossref","first-page":"17411","DOI":"10.3390\/ijms151017411","article-title":"The biological function and clinical utilization of CD147 in human diseases: a review of the current scientific literature","volume":"15","author":"Xiong","year":"2014","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103046_b0315","article-title":"Role of CD147 in the development and diagnosis of hepatocellular carcinoma","volume":"14\u20132023","author":"Huang","year":"2023","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0320","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/hepr.12320","article-title":"Expression and clinical implications of HAb18G\/CD147 in hepatocellular carcinoma","volume":"45","author":"Zhu","year":"2015","journal-title":"Hepatol Res"},{"key":"10.1016\/j.ctrv.2025.103046_b0325","doi-asserted-by":"crossref","first-page":"233","DOI":"10.3389\/fcell.2019.00233","article-title":"Doxycycline Inducible Chimeric Antigen Receptor T Cells Targeting CD147 for Hepatocellular Carcinoma Therapy","volume":"7","author":"Zhang","year":"2019","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0330","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1038\/s41467-020-18444-2","article-title":"Efficacy of anti-CD147 chimeric antigen receptors targeting hepatocellular carcinoma","volume":"11","author":"Tseng","year":"2020","journal-title":"Nat Commun"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0335","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/toxins8060165","article-title":"CD133, Selectively Targeting the root of Cancer","volume":"8","author":"Schmohl","year":"2016","journal-title":"Toxins"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0340","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2009.12.030","article-title":"Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma","volume":"52","author":"Kohga","year":"2010","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0345","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/j.1742-1241.2008.01777.x","article-title":"Expression and clinical significance of the stem cell marker CD133 in hepatocellular carcinoma","volume":"62","author":"Song","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103046_b0350","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1440169","article-title":"CD133-directed CAR T cells for advanced metastasis malignancies: a phase I trial","volume":"7","author":"Wang","year":"2018","journal-title":"Oncoimmunology"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0355","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1186\/s12885-022-09861-1","article-title":"Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0360","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1186\/s12916-023-03016-0","article-title":"Targeted delivery of a PD-1-blocking scFv by CD133-specific CAR-T cells using nonviral sleeping beauty transposition shows enhanced antitumour efficacy for advanced hepatocellular carcinoma","volume":"21","author":"Yang","year":"2023","journal-title":"BMC Med"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0365","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ejca.2008.01.022","article-title":"Molecular cancer therapy: can our expectation be MET?","volume":"44","author":"Migliore","year":"2008","journal-title":"Eur J Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0370","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","article-title":"Tyrosine kinase signaling-independent MET-targeting with CAR-T cells","volume":"21","author":"Qin","year":"2023","journal-title":"J Transl Med"},{"key":"10.1016\/j.ctrv.2025.103046_b0375","article-title":"Bispecific c-Met\/PD-L1 CAR-T Cells have Enhanced Therapeutic Effects on Hepatocellular Carcinoma","volume":"11","author":"Jiang","year":"2021","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0380","doi-asserted-by":"crossref","first-page":"10","DOI":"10.7555\/JBR.35.20200207","article-title":"c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo","volume":"36","author":"Huang","year":"2021","journal-title":"J Biomed Res"},{"issue":"12","key":"10.1016\/j.ctrv.2025.103046_b0385","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat Rev Cancer"},{"issue":"22","key":"10.1016\/j.ctrv.2025.103046_b0390","doi-asserted-by":"crossref","first-page":"19264","DOI":"10.18632\/oncotarget.4267","article-title":"Mucin1 promotes the migration and invasion of hepatocellular carcinoma cells via JNK-mediated phosphorylation of Smad2 at the C-terminal and linker regions","volume":"6","author":"Wang","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2025.103046_b0395","article-title":"Specific cytotoxicity of MUC1 chimeric antigen receptor-engineered Jurkat T cells against hepatocellular carcinoma","volume":"1177\u201382","author":"Yi-Dong","year":"2014","journal-title":"Acad J Second Mil Med Uni"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0400","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2009.10.026","article-title":"EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma","volume":"52","author":"Terris","year":"2010","journal-title":"J Hepatol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0405","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1158\/0008-5472.CAN-07-6013","article-title":"EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma","volume":"68","author":"Yamashita","year":"2008","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103046_b0410","first-page":"1947","article-title":"EpCAM-targeting CAR-T cells against hepatoma cells in vitro","volume":"45","author":"Wang","year":"2023","journal-title":"Journal of Army Medical University"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0415","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1158\/1535-7163.MCT-11-0531","article-title":"DLK1 as a potential target against cancer stem\/progenitor cells of hepatocellular carcinoma","volume":"11","author":"Xu","year":"2012","journal-title":"Mol Cancer Ther"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0420","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.21873\/anticanres.11430","article-title":"Elevated Preoperative Serum CEA Level is Associated with Poor Prognosis in patients with Hepatocellular Carcinoma through the Epithelial-Mesenchymal transition","volume":"37","author":"Yoshikawa","year":"2017","journal-title":"Anticancer Res"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103046_b0425","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1111\/liv.15411","article-title":"DLK1-directed chimeric antigen receptor T-cell therapy for hepatocellular carcinoma","volume":"42","author":"Zhai","year":"2022","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103046_b0430","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00262-015-1692-6","article-title":"Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T","volume":"64","author":"Burga","year":"2015","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0435","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/(SICI)1097-0142(19990315)85:6<1234::AID-CNCR4>3.0.CO;2-7","article-title":"Expression of the MAGE gene family in human hepatocellular carcinoma","volume":"85","author":"Tahara","year":"1999","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0440","first-page":"219","article-title":"High expression of MAGE-A9 contributes to stemness and malignancy of human hepatocellular carcinoma","volume":"52","author":"Wei","year":"2018","journal-title":"Int J Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2025.103046_b0445","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1158\/0008-5472.CAN-19-2691","article-title":"Interaction with CD68 and Regulation of GAS6 Expression by Endosialin in Fibroblasts Drives Recruitment and Polarization of Macrophages in Hepatocellular Carcinoma","volume":"80","author":"Yang","year":"2020","journal-title":"Cancer Res"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0450","article-title":"Soluble trivalent engagers redirect cytolytic T cell activity toward tumor endothelial marker 1","volume":"2","author":"Fierle","year":"2021","journal-title":"Cell Rep Med"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0455","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1440-1746.2006.04271.x","article-title":"Expression and immunogenicity of NY-ESO-1 in hepatocellular carcinoma","volume":"21","author":"Nakamura","year":"2006","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0460","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004035","article-title":"Development of a TCR-like antibody and chimeric antigen receptor against NY-ESO-1\/HLA-A2 for cancer immunotherapy","volume":"10","author":"Liu","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"15","key":"10.1016\/j.ctrv.2025.103046_b0465","doi-asserted-by":"crossref","first-page":"3979","DOI":"10.1158\/1078-0432.CCR-19-3259","article-title":"Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: results of phase I Trials","volume":"26","author":"Shi","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103046_b0470","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2025.43.16_suppl.4084","article-title":"Phase I study of Ori-C101, an armored GPC3-directed CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","author":"Fan","year":"2025","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103046_b0475","article-title":"Phase I study of C-CAR031, a GPC3-specific TGF\u03b2RIIDN armored autologous CAR-T, in patients with advanced hepatocellular carcinoma (HCC)","author":"Zhang","year":"2024","journal-title":"Proc Am Soc Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0480","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.ctrv.2025.103046_b0485","article-title":"Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report","volume":"13","author":"Sun","year":"2022","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0490","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1016\/j.ymthe.2022.12.009","article-title":"Enforced expression of Runx3 improved CAR-T cell potency in solid tumor via enhancing resistance to activation-induced cell death","volume":"31","author":"Wang","year":"2023","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2025.103046_b0495","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102175","article-title":"RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial","volume":"63","author":"Fu","year":"2023","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0500","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1846926","article-title":"Efficacy and biomarker analysis of CD133-directed CAR T cells in advanced hepatocellular carcinoma: a single-arm, open-label, phase II trial","volume":"9","author":"Dai","year":"2020","journal-title":"Oncoimmunology"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0505","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/s41417-019-0104-z","article-title":"HITM-SIR: phase Ib trial of intraarterial chimeric antigen receptor T-cell therapy and selective internal radiation therapy for CEA(+) liver metastases","volume":"27","author":"Katz","year":"2020","journal-title":"Cancer Gene Ther"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103046_b0510","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103046_b0515","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1200\/EDBK_238691","article-title":"The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden","volume":"39","author":"Santomasso","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"20","key":"10.1016\/j.ctrv.2025.103046_b0520","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2025.103046_b0525","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3389\/fimmu.2020.01973","article-title":"Neurotoxicity and Cytokine Release Syndrome after Chimeric Antigen Receptor T Cell Therapy: Insights into Mechanisms and Novel Therapies","volume":"11","author":"Siegler","year":"2020","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103046_b0530","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/j.jcyt.2022.03.008","article-title":"Rational design of chimeric antigen receptor T cells against glypican 3 decouples toxicity from therapeutic efficacy","volume":"24","author":"Giardino Torchia","year":"2022","journal-title":"Cytotherapy"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0535","doi-asserted-by":"crossref","first-page":"e98","DOI":"10.1038\/ctg.2017.28","article-title":"Targeting the vasculature in hepatocellular carcinoma treatment: Starving versus normalizing blood supply","volume":"8","author":"Liu","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0540","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084170","article-title":"Car T Cells in Solid Tumors: Overcoming Obstacles","volume":"25","author":"Rojas-Quintero","year":"2024","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103046_b0545","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu Rev Med"},{"issue":"16","key":"10.1016\/j.ctrv.2025.103046_b0550","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1089\/10430340260355374","article-title":"Redirecting migration of T cells to chemokine secreted from tumors by genetic modification with CXCR2","volume":"13","author":"Kershaw","year":"2002","journal-title":"Hum Gene Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0555","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/eji.201948457","article-title":"CXCR2-modified CAR-T cells have enhanced trafficking ability that improves treatment of hepatocellular carcinoma","volume":"50","author":"Liu","year":"2020","journal-title":"Eur J Immunol"},{"key":"10.1016\/j.ctrv.2025.103046_b0560","doi-asserted-by":"crossref","unstructured":"ElGhandour AM, Bayoumy EM, Ibrahim WA, Sayed MM, Salama AB, Teama NM, et al. Vascular endothelial growth factor in relation to the development of hepatocellular carcinoma in hepatitis C virus patients treated by direct-acting antivirals. Egyptian Liver Journal. 2021;11(1):5.","DOI":"10.1186\/s43066-020-00073-5"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0565","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.dld.2023.09.019","article-title":"HIF-1\u03b1 and VEGF as prognostic biomarkers in hepatocellular carcinoma patients treated with transarterial chemoembolization","volume":"56","author":"Pinto","year":"2024","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.ctrv.2025.103046_b0570","article-title":"Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: current process and potential application","volume":"13","author":"Yang","year":"2023","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0575","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005583","article-title":"Anti-VEGF therapy improves EGFR-vIII-CAR-T cell delivery and efficacy in syngeneic glioblastoma models in mice","volume":"11","author":"Dong","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0580","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-002151","article-title":"VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding","volume":"9","author":"Lanitis","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103046_b0585","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1226360","article-title":"Immunotherapies targeting tumor vasculature: challenges and opportunities","volume":"14","author":"Dianat-Moghadam","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.103046_b0590","doi-asserted-by":"crossref","first-page":"26","DOI":"10.20517\/2394-5079.2018.27","article-title":"Hypoxic microenvironment and hepatocellular carcinoma treatment","volume":"4","author":"Ci-Ai","year":"2018","journal-title":"Hepatoma Research"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0595","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1038\/mt.2013.110","article-title":"Antitumor effects of chimeric receptor engineered human T cells directed to tumor stroma","volume":"21","author":"Kakarla","year":"2013","journal-title":"Mol Ther"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0600","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s13402-021-00602-3","article-title":"Angiogenesis as a hallmark of solid tumors - clinical perspectives","volume":"44","author":"Majidpoor","year":"2021","journal-title":"Cell Oncol (Dordr)"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0605","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-\u03b2-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"St\u00fcber","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0610","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1038\/nm.3833","article-title":"Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes","volume":"21","author":"Caruana","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2025.103046_b0615","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.1034257","article-title":"Mechanisms of CAR T cell exhaustion and current counteraction strategies","volume":"10","author":"Zhu","year":"2022","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0620","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-Responsive CAR-T Cells exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0625","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s40364-024-00602-z","article-title":"CRISPR\/Cas-based CAR-T cells: production and application","volume":"12","author":"Song","year":"2024","journal-title":"Biomarker Res"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103046_b0630","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0635","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor activity by reducing mTORC1 activity and Preserving their Stem Cell memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0640","doi-asserted-by":"crossref","first-page":"198","DOI":"10.4049\/jimmunol.1800033","article-title":"Armored Inducible Expression of IL-12 Enhances Antitumor activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma","volume":"203","author":"Liu","year":"2019","journal-title":"J Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0645","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006522","article-title":"Metabolic reprogramming via an engineered PGC-1\u03b1 improves human chimeric antigen receptor T-cell therapy against solid tumors","volume":"11","author":"Lontos","year":"2023","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103046_b0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.109333","article-title":"Chimeric antigen receptor modified T cell (CAR-T) co-expressed with ICOSL-41BB promote CAR-T proliferation and tumor rejection","volume":"118","author":"Hu","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0655","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2018.1509173","article-title":"DNAX-activating protein 10 co-stimulation enhances the anti-tumor efficacy of chimeric antigen receptor T cells","volume":"8","author":"Zhao","year":"2019","journal-title":"Oncoimmunology"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0660","doi-asserted-by":"crossref","first-page":"216","DOI":"10.3748\/wjg.v28.i2.216","article-title":"Update on the applications and limitations of alpha-fetoprotein for hepatocellular carcinoma","volume":"28","author":"Hanif","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0665","first-page":"71","article-title":"EpCAM as a novel therapeutic target for hepatocellular carcinoma. Journal of Oncological","volume":"3","author":"S v, p s, m p, v b, b v, s g.","year":"2017","journal-title":"Sciences"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0670","doi-asserted-by":"crossref","first-page":"161","DOI":"10.3892\/mco.2022.2594","article-title":"Expression of MUC1 in different tumours and its clinical significance (Review)","volume":"17","author":"Lan","year":"2022","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0675","article-title":"Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma. Molecular Therapy","volume":"32","author":"Zhou","year":"2024","journal-title":"Oncology"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0680","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1038\/s41571-022-00704-3","article-title":"Overcoming on-target, off-tumour toxicity of CAR T cell therapy for solid tumours","volume":"20","author":"Flugel","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2025.103046_b0685","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241309825","article-title":"Severe refractory colitis after intraperitoneal infusion of CEA-directed CAR T cells in patients with colorectal cancer","volume":"16","author":"Ye","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0690","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-004185","article-title":"To go or not to go? Biological logic gating engineered T cells","volume":"10","author":"Abbott","year":"2022","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103046_b0695","article-title":"Logic-gated and contextual control of immunotherapy for solid tumors: contrasting multi-specific T cell engagers and CAR-T cell therapies","volume":"15\u20132024","author":"Nolan-Stevaux","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.103046_b0700","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1545270","article-title":"SynNotch CAR-T cell, when synthetic biology and immunology meet again","volume":"16","author":"Shirzadian","year":"2025","journal-title":"Front Immunol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0705","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2019.02.003","article-title":"Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting","volume":"35","author":"Srivastava","year":"2019","journal-title":"Cancer Cell"},{"issue":"7952","key":"10.1016\/j.ctrv.2025.103046_b0710","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41586-023-05778-2","article-title":"Co-opting signalling molecules enables logic-gated control of CAR T cells","volume":"615","author":"Tousley","year":"2023","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0715","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1158\/2159-8290.CD-23-0101","article-title":"Programming CAR T Cell Tumor Recognition: Tuned Antigen Sensing and Logic Gating","volume":"13","author":"Hamieh","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0720","first-page":"156","article-title":"Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy","volume":"13","author":"Li","year":"2021","journal-title":"Am J Transl Res"},{"key":"10.1016\/j.ctrv.2025.103046_b0725","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/8363265","article-title":"Total HLA Class I Antigen loss with the Downregulation of Antigen-Processing Machinery Components in two newly established Sarcomatoid Hepatocellular Carcinoma Cell Lines","volume":"2018","author":"Lei","year":"2018","journal-title":"J Immunol Res"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0730","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.14101","article-title":"Antigen loss following CAR-T cell therapy: Mechanisms, implications, and potential solutions","volume":"112","author":"Mishra","year":"2024","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0735","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s12094-020-02490-9","article-title":"Programmable and multi-targeted CARs: a new breakthrough in cancer CAR-T cell therapy","volume":"23","author":"Tahmasebi","year":"2021","journal-title":"Clin Transl Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0740","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00262-016-1949-8","article-title":"Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma","volume":"66","author":"Chen","year":"2017","journal-title":"Cancer Immunol Immunother"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0745","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1038\/s41467-024-47801-8","article-title":"Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed\/refractory multiple myeloma: a phase I\/II trial","volume":"15","author":"Shi","year":"2024","journal-title":"Nat Commun"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0750","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1080\/14712598.2022.2086043","article-title":"Bispecific CAR T-cells for B-cell Malignancies","volume":"22","author":"Furqan","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2025.103046_b0755","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2021.104295","article-title":"MDSCs in liver cancer: a critical tumor-promoting player and a potential therapeutic target","volume":"361","author":"Ma","year":"2021","journal-title":"Cell Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0760","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/s41420-023-01356-7","article-title":"Targeting tumor-associated macrophages in hepatocellular carcinoma: biology, strategy, and immunotherapy","volume":"9","author":"Zheng","year":"2023","journal-title":"Cell Death Discovery"},{"issue":"27","key":"10.1016\/j.ctrv.2025.103046_b0765","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.3748\/wjg.v28.i27.3346","article-title":"Regulatory T cells and their associated factors in hepatocellular carcinoma development and therapy","volume":"28","author":"Zhang","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103046_b0770","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.3748\/wjg.v9.i9.1946","article-title":"Pathomorphological study on location and distribution of Kupffer cells in hepatocellular carcinoma","volume":"9","author":"Liu","year":"2003","journal-title":"World J Gastroenterol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103046_b0775","doi-asserted-by":"crossref","first-page":"935","DOI":"10.2217\/imt-2018-0012","article-title":"Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages","volume":"10","author":"Zhang","year":"2018","journal-title":"Immunotherapy"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b0780","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1158\/1535-7163.MCT-20-0591","article-title":"CSF1\/CSF1R Signaling Inhibitor Pexidartinib (PLX3397) Reprograms Tumor-Associated Macrophages and Stimulates T-cell Infiltration in the Sarcoma Microenvironment","volume":"20","author":"Fujiwara","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ctrv.2025.103046_b0785","article-title":"Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy","volume":"6(237):237ra67","author":"Highfill","year":"2014","journal-title":"Sci Transl Med"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103046_b0790","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T-cell modulation using cyclophosphamide in vaccine approaches: a current perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103046_b0795","doi-asserted-by":"crossref","first-page":"2624","DOI":"10.1021\/acs.bioconjchem.9b00547","article-title":"The effect of Antibody Fragments on CD25 Targeted Regulatory T Cell Near-Infrared Photoimmunotherapy","volume":"30","author":"Okada","year":"2019","journal-title":"Bioconjug Chem"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2025.103046_b0800","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1182\/blood-2020-142228","article-title":"CXCR4-Expressing Anti-CD25 CAR T-Cells Effectively eliminate Human AML Cells In Vivo","volume":"136","author":"Itoh-Nakadai","year":"2020","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0805","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1677\/joe.1.06585","article-title":"Inactivation of Kupffer cells by gadolinium administration prevents lipopolysaccharide-induced decrease in liver insulin-like growth factor-I and IGF-binding protein-3 gene expression","volume":"188","author":"Granado","year":"2006","journal-title":"J Endocrinol"},{"key":"10.1016\/j.ctrv.2025.103046_b0810","article-title":"109\u2005Dominant-negative TGF\u03b2 receptor 2 enhances GPC3-targeting CAR-T cell efficacy against hepatocellular carcinoma","volume":"8(Suppl","author":"Chu","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103046_b0815","article-title":"Rational design of TGFbRII dominant negative armored GPC3 CAR-T cells for the treatment of hepatocellular carcinoma","volume":"210(1_Supplement):68.17-68.17","author":"Merlino","year":"2023","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e12688","article-title":"PD-1 blocking strategy for enhancing the anti-tumor effect of CAR T cells targeted CD105","volume":"9","author":"Wang","year":"2023","journal-title":"Heliyon"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0825","doi-asserted-by":"crossref","first-page":"165","DOI":"10.4254\/wjh.v7.i2.165","article-title":"Targeting the tumor stroma in hepatocellular carcinoma","volume":"7","author":"Heindryckx","year":"2015","journal-title":"World J Hepatol"},{"issue":"14","key":"10.1016\/j.ctrv.2025.103046_b0830","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411471","article-title":"Immune System and Hepatocellular Carcinoma (HCC): New Insights into HCC Progression","volume":"24","author":"Kotsari","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0835","first-page":"3","article-title":"Hypoxia\u2011inducible factors in hepatocellular carcinoma (Review)","volume":"43","author":"Guo","year":"2020","journal-title":"Oncol Rep"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103046_b0840","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0845","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1021\/acscentsci.2c00163","article-title":"Bioorthogonal Equipping CAR-T Cells with Hyaluronidase and Checkpoint Blocking Antibody for Enhanced Solid Tumor Immunotherapy","volume":"8","author":"Zhao","year":"2022","journal-title":"ACS Cent Sci"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b0850","article-title":"Targeting hepatocellular carcinoma heterogeneity with FAP and GPC3-specific tandem CAR-T cells","volume":"32","author":"Li","year":"2024","journal-title":"Molecular Therapy: Oncology"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103046_b0855","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002755","article-title":"Conditioned CAR-T cells by hypoxia-inducible transcription amplification (HiTA) system significantly enhances systemic safety and retains antitumor efficacy","volume":"9","author":"He","year":"2021","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ctrv.2025.103046_b0860","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105829","article-title":"Lenvatinib enhances T cell immunity and the efficacy of adoptive chimeric antigen receptor-modified T cells by decreasing myeloid-derived suppressor cells in cancer","volume":"174","author":"Lu","year":"2021","journal-title":"Pharmacol Res"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0865","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1158\/0008-5472.CAN-23-1038","article-title":"Hypoxia-Responsive CAR-T Cells exhibit Reduced Exhaustion and Enhanced Efficacy in Solid Tumors","volume":"84","author":"Zhu","year":"2024","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2025.103046_b0870","article-title":"Metabolic challenges and interventions in CAR T cell therapy","volume":"8(82):eabq3016","author":"Peng","year":"2023","journal-title":"Sci Immunol"},{"issue":"10\u201311","key":"10.1016\/j.ctrv.2025.103046_b0875","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1038\/s41417-020-00259-4","article-title":"Recent updates on chimeric antigen receptor T cell therapy for hepatocellular carcinoma","volume":"28","author":"Guo","year":"2021","journal-title":"Cancer Gene Ther"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0880","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3892\/ol.2022.13404","article-title":"Hypoxia-inducible factor-1\u03b1: a critical target for inhibiting the metastasis of hepatocellular carcinoma","volume":"24","author":"Chen","year":"2022","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0885","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41392-023-01332-8","article-title":"Hypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.ctrv.2025.103046_b0890","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155747","article-title":"The role of ROS in tumor infiltrating immune cells and cancer immunotherapy","volume":"151","author":"Shah","year":"2024","journal-title":"Metabolism"},{"issue":"2","key":"10.1016\/j.ctrv.2025.103046_b0895","doi-asserted-by":"crossref","first-page":"759","DOI":"10.4049\/jimmunol.1401710","article-title":"Coexpressed Catalase Protects Chimeric Antigen Receptor-Redirected T Cells as well as Bystander Cells from Oxidative Stress-Induced loss of Antitumor activity","volume":"196","author":"Ligtenberg","year":"2016","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0900","doi-asserted-by":"crossref","first-page":"3236","DOI":"10.1038\/s41467-021-23331-5","article-title":"CRISPR\/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy","volume":"12","author":"Giuffrida","year":"2021","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0905","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2020.1824643","article-title":"Improving the anti-solid tumor efficacy of CAR-T cells by inhibiting adenosine signaling pathway","volume":"9","author":"Li","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ctrv.2025.103046_b0910","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1083303","article-title":"The potential role of short chain fatty acids improving ex vivo T and CAR-T cell fitness and expansion for cancer immunotherapies","volume":"14","author":"Gonz\u00e1lez-Brito","year":"2023","journal-title":"Front Immunol"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0915","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/hep.27246","article-title":"Immune checkpoint blockade in hepatocellular carcinoma: current progress and future directions","volume":"60","author":"Hato","year":"2014","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0920","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1186\/s12885-023-11298-z","article-title":"Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0925","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctrv.2025.103046_b0930","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.3389\/fphar.2018.01118","article-title":"Disruption of PD-1 Enhanced the Anti-tumor activity of Chimeric Antigen Receptor T Cells against Hepatocellular Carcinoma","volume":"9","author":"Guo","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0935","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1038\/s41598-017-00462-8","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells","volume":"7","author":"Rupp","year":"2017","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.ctrv.2025.103046_b0940","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1007\/s00262-018-2221-1","article-title":"Increased antitumor activities of glypican-3-specific chimeric antigen receptor-modified T cells by coexpression of a soluble PD1-CH3 fusion protein","volume":"67","author":"Pan","year":"2018","journal-title":"Cancer Immunol Immunother"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103046_b0945","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/nbt.4195","article-title":"Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo","volume":"36","author":"Rafiq","year":"2018","journal-title":"Nat Biotechnol"},{"issue":"625","key":"10.1016\/j.ctrv.2025.103046_b0950","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aay8248","article-title":"4-1BB costimulation promotes CAR T cell survival through noncanonical NF-\u03baB signaling","volume":"13","author":"Philipson","year":"2020","journal-title":"Sci Signal"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b0955","doi-asserted-by":"crossref","first-page":"35","DOI":"10.5114\/ceh.2018.73484","article-title":"Evaluation of serum interleukin-10 levels in hepatocellular carcinoma patients: a systematic review and meta-analysis","volume":"4","author":"Shakiba","year":"2018","journal-title":"Clin Exp Hepatol"},{"issue":"13","key":"10.1016\/j.ctrv.2025.103046_b0960","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13133248","article-title":"The TGF-\u03b2 Pathway: a Pharmacological Target in Hepatocellular Carcinoma?","volume":"13","author":"Gonzalez-Sanchez","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0965","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid Tumors challenges and New Insights of CAR T Cell Engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev Rep"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b0970","doi-asserted-by":"crossref","first-page":"e123","DOI":"10.1016\/j.bbmt.2018.12.756","article-title":"Cytokine Release Syndrome with Chimeric Antigen Receptor T Cell Therapy","volume":"25","author":"Frey","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"10.1016\/j.ctrv.2025.103046_b0975","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1016\/j.ymthe.2018.05.003","article-title":"Dominant-negative TGF-\u03b2 Receptor Enhances PSMA-Targeted Human CAR T Cell Proliferation and Augments Prostate Cancer Eradication","volume":"26","author":"Kloss","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.ctrv.2025.103046_b0980","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.684642","article-title":"Engineered Cytokine Signaling to Improve CAR T Cell Effector Function","volume":"12","author":"Bell","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.103046_b0985","doi-asserted-by":"crossref","first-page":"235","DOI":"10.3389\/fphar.2014.00235","article-title":"The inducible caspase-9 suicide gene system as a \u201csafety switch\u201d to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells","volume":"5","author":"Gargett","year":"2014","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b0990","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/leu.2010.75","article-title":"Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma\/leukemia effects and safety","volume":"24","author":"Hoyos","year":"2010","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b0995","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","article-title":"A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells","volume":"118","author":"Wang","year":"2011","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ctrv.2025.103046_b1000","article-title":"Photothermal Therapy Promotes Tumor Infiltration and Antitumor activity of CAR T Cells","volume":"31","author":"Chen","year":"2019","journal-title":"Adv Mater"},{"key":"10.1016\/j.ctrv.2025.103046_b1005","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.75660","article-title":"De novo-designed transmembrane domains tune engineered receptor functions","volume":"11","author":"Elazar","year":"2022","journal-title":"Elife"},{"key":"10.1016\/j.ctrv.2025.103046_b1010","article-title":"The pathogenesis, diagnosis, prevention, and treatment of CAR-T cell therapy-related adverse reactions","volume":"13","author":"Li","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ctrv.2025.103046_b1015","article-title":"A phase I study of GPC3 targeted CAR-T cell therapy in advanced GPC3-expressing hepatocellular carcinoma (HCC)","volume":"41(4_suppl):TPS624-TPS","author":"Xie","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b1020","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/life15010034","article-title":"Role of Coagulation Factors in Hepatocellular Carcinoma: a Literature Review","volume":"15","author":"Azam","year":"2025","journal-title":"Life"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b1025","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jmii.2015.03.001","article-title":"IL-6 significantly correlates with p-STAT3 expression and presents high variceal bleeding with mortality in cirrhotic patients: a cross-sectional study","volume":"50","author":"Kao","year":"2017","journal-title":"J Microbiol Immunol Infect"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b1030","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000621","article-title":"Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies","volume":"8","author":"Kauer","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b1035","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MCG.0b013e31818a3854","article-title":"Acetaminophen hepatotoxicity and acute liver failure","volume":"43","author":"Chun","year":"2009","journal-title":"J Clin Gastroenterol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103046_b1040","doi-asserted-by":"crossref","first-page":"3953","DOI":"10.1172\/JCI43490","article-title":"Gene therapy using genetically modified lymphocytes targeting VEGFR-2 inhibits the growth of vascularized syngenic tumors in mice","volume":"120","author":"Chinnasamy","year":"2010","journal-title":"J Clin Invest"},{"issue":"8","key":"10.1016\/j.ctrv.2025.103046_b1045","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/s41577-018-0014-6","article-title":"Integrating oncolytic viruses in combination cancer immunotherapy","volume":"18","author":"Bommareddy","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2025.103046_b1050","article-title":"Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice","volume":"14(640):eabn2231","author":"Evgin","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ctrv.2025.103046_b1055","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"issue":"11","key":"10.1016\/j.ctrv.2025.103046_b1060","doi-asserted-by":"crossref","first-page":"3321","DOI":"10.12998\/wjcc.v10.i11.3321","article-title":"Encouraging specific biomarkers-based therapeutic strategies for hepatocellular carcinoma","volume":"10","author":"Yao","year":"2022","journal-title":"World J Clin Cases"},{"issue":"4","key":"10.1016\/j.ctrv.2025.103046_b1065","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001875","article-title":"Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma","volume":"9","author":"Sun","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b1070","doi-asserted-by":"crossref","first-page":"2539","DOI":"10.3390\/ijms24032539","article-title":"The Role of Alpha-Fetoprotein (AFP) in Contemporary Oncology: the Path from a Diagnostic Biomarker to an Anticancer Drug","volume":"24","author":"G\u0142owska-Ciemny","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctrv.2025.103046_b1075","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1363695","article-title":"The role of alpha-fetoprotein in the tumor microenvironment of hepatocellular carcinoma","volume":"14","author":"Lu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2025.103046_b1080","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1489649","article-title":"CAR-T cell therapy for hepatocellular carcinoma: current trends and challenges","volume":"15","author":"Zhou","year":"2024","journal-title":"Front Immunol"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b1085","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","article-title":"CAR-T cell therapy for cancer: current challenges and future directions","volume":"10","author":"Zugasti","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.ctrv.2025.103046_b1090","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b1095","article-title":"Transarterial Chemoembolization for Hepatocellular Carcinoma: why","volume":"12","author":"Kotsifa","year":"2022","journal-title":"When, How? J Pers Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b1100","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ila2.8","article-title":"Target selection and clinical chimeric antigen receptor T cell activity against solid tumors","volume":"1","author":"von Hofe","year":"2023","journal-title":"iLABMED"},{"key":"10.1016\/j.ctrv.2025.103046_b1105","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2022.797440","article-title":"Chimeric Antigen Receptor T-Cells: an Overview of Concepts, applications, Limitations, and Proposed Solutions","volume":"10","author":"Alnefaie","year":"2022","journal-title":"Front Bioeng Biotechnol"},{"key":"10.1016\/j.ctrv.2025.103046_b1110","article-title":"CAR T Cells for Solid Tumors: New strategies for Finding, Infiltrating, and surviving in the Tumor Microenvironment","volume":"10\u20132019","author":"Martinez","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.ctrv.2025.103046_b1115","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2024.100739","article-title":"Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy","volume":"24","author":"Carcopino","year":"2024","journal-title":"Immuno-Oncology and Technology"},{"key":"10.1016\/j.ctrv.2025.103046_b1120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176618","article-title":"Improving chimeric antigen receptor T-cell therapies by using artificial intelligence and internet of things technologies: a narrative review","volume":"974","author":"Boretti","year":"2024","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.ctrv.2025.103046_b1125","article-title":"Artificial intelligence for chimeric antigen receptor-based therapies: a comprehensive review of current applications and future perspectives","volume":"12","author":"Shahzadi","year":"2024","journal-title":"Ther Adv Vaccines Immunother"},{"key":"10.1016\/j.ctrv.2025.103046_b1130","doi-asserted-by":"crossref","DOI":"10.3389\/fmmed.2023.1250508","article-title":"Elaborating the potential of Artificial Intelligence in automated CAR-T cell manufacturing","volume":"3","author":"B\u00e4ckel","year":"2023","journal-title":"Front Mol Med"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b1135","first-page":"14","article-title":"The role of glypican-3 in regulating Wnt in hepatocellular carcinomas","volume":"1","author":"Gao","year":"2011","journal-title":"Cancer Rep"},{"key":"10.1016\/j.ctrv.2025.103046_b1140","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.canlet.2019.11.043","article-title":"Acetylation of alpha-fetoprotein promotes hepatocellular carcinoma progression","volume":"471","author":"Xue","year":"2020","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ctrv.2025.103046_b1145","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fimmu.2015.00097","article-title":"NKG2D Ligands in Tumor Immunity: two Sides of a Coin","volume":"6","author":"Zhang","year":"2015","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.ctrv.2025.103046_b1150","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/j.jhep.2009.12.030","article-title":"Expression of CD133 confers malignant potential by regulating metalloproteinases in human hepatocellular carcinoma","volume":"52","author":"Kohga","year":"2010","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.ctrv.2025.103046_b1155","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1002\/hep.24450","article-title":"c-Met represents a potential therapeutic target for personalized treatment in hepatocellular carcinoma","volume":"54","author":"You","year":"2011","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b1160","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/bjc.1978.162","article-title":"Carcinoembryonic antigen in hepatocellular cancer","volume":"38","author":"Macnab","year":"1978","journal-title":"Br J Cancer"},{"issue":"9","key":"10.1016\/j.ctrv.2025.103046_b1165","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1073\/pnas.0511306103","article-title":"Tumor endothelial marker 1 (Tem1) functions in the growth and progression of abdominal tumors","volume":"103","author":"Nanda","year":"2006","journal-title":"PNAS"},{"issue":"1","key":"10.1016\/j.ctrv.2025.103046_b1170","doi-asserted-by":"crossref","first-page":"39","DOI":"10.3892\/ol.2011.441","article-title":"NY-ESO-1 expression in hepatocellular carcinoma: a potential new marker for early recurrence after surgery","volume":"3","author":"Xu","year":"2012","journal-title":"Oncol Lett"},{"key":"10.1016\/j.ctrv.2025.103046_b1175","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2023.116109","article-title":"Claudins and hepatocellular carcinoma","volume":"171","author":"Wang","year":"2024","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.ctrv.2025.103046_b1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.onano.2023.100124","article-title":"Nano-immunoengineering of CAR-T cell therapy against tumor microenvironment: the way forward in combating cancer","volume":"10","author":"Khawar","year":"2023","journal-title":"OpenNano"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737225001689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T07:50:40Z","timestamp":1764143440000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737225001689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":236,"alternative-id":["S0305737225001689"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103046","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2025.103046","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103046"}}